Evidence map›Paper›PMID 32458231›Full record

ArticleSurgery today2020

Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.

Yoko Oshima, Takashi Suzuki, Satoshi Yajima, Tatsuki Nanami, Fumiaki Shiratori, Kimihiko Funahashi, Hideaki Shimada

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yoko OshimaDepartment of Surgery, Toho University School of Medicine, Tokyo, Japan.
Takashi SuzukiDepartment of Surgery, Toho University School of Medicine, Tokyo, Japan.
Satoshi YajimaDepartment of Surgery, Toho University School of Medicine, Tokyo, Japan.
Tatsuki NanamiDepartment of Surgery, Toho University School of Medicine, Tokyo, Japan.
Fumiaki ShiratoriDepartment of Surgery, Toho University School of Medicine, Tokyo, Japan.
Kimihiko FunahashiDepartment of Surgery, Toho University School of Medicine, Tokyo, Japan.
Hideaki ShimadaDepartment of Surgery, Toho University School of Medicine, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.ORCID http://orcid.org/0000-0002-1990-8217
Toho University · JP

Funding

JSPS KAKENHI 26462029
6 · The paper itself

Abstract

purposeTo establish the clinicopathological importance of serum p53 autoantibody (s-p53-Ab) titrations in patients with gastric cancer.

methodsPreoperative s-p53-Ab titers were analyzed in 448 gastric cancer patients between 2010 and 2017. Seropositive patients were divided into three groups based on their antibody titers: 1.31-10.0 U/mL (low group); 10.1-100 U/mL (medium group); and > 100 U/mL (high group). We evaluated the associations between the s-p53-Abs and clinicopathological factors, carcinoembryonic antigen (CEA) levels, and cancer antigen 19-9 (CA19-9) levels. Overall survival was analyzed by multivariate analyses.

resultsA total of 72 patients (16%) were positive for s-p53-Abs. The rate of positivity for s-p53-Abs + CEA + CA19-9 was significantly higher than that for CEA + CA19-9, even in stage I gastric cancers. Gender, tumor depth, lymphatic node metastases, and distant metastases were all significantly associated with the presence of s-p53-Abs; however, overall survival was not associated with the antibodies. The patients in the high titer group (> 100 U/mL) had a relatively worse survival than those in the other groups.

conclusionsBased on our findings, s-p53-Abs improve the overall rate of positivity for detecting gastric cancer, but the prognostic value of a high s-p53-Ab titer for predicting overall survival is limited.

Indexed as

AdultAgedAged, 80 and overAutoantibodiesBiomarkers, TumorEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoblottingMaleMiddle AgedMutationPrognosisStomach NeoplasmsTumor Suppressor Protein p53AutoantibodiesBiomarkers, TumorTumor Suppressor Protein p53Antibody titerGastric cancerPrognosisSerum p53 antibody

Identifiers

PMID32458231
OpenAlexW3028632805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.